NASDAQ:OPNT - Opiant Pharmaceuticals Stock Price, Forecast & News

Opiant Pharmaceuticals' stock was trading at $10.85 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, OPNT shares have decreased by 10.6% and is now trading at $9.70. View which stocks have been mosted impacted by Coronavirus.

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Opiant Pharmaceuticals in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Opiant Pharmaceuticals.

Opiant Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Opiant Pharmaceuticals.

Opiant Pharmaceuticals Inc (NASDAQ:OPNT) posted its quarterly earnings results on Wednesday, March, 4th. The technology company reported $0.20 EPS for the quarter, missing the Thomson Reuters' consensus estimate of $0.31 by $0.11. The technology company had revenue of $7.67 million for the quarter, compared to the consensus estimate of $7.70 million. Opiant Pharmaceuticals had a net margin of 28.61% and a return on equity of 3.61%. View Opiant Pharmaceuticals' earnings history.

1 brokerages have issued twelve-month price targets for Opiant Pharmaceuticals' shares. Their forecasts range from $42.00 to $42.00. On average, they expect Opiant Pharmaceuticals' share price to reach $42.00 in the next twelve months. This suggests a possible upside of 333.0% from the stock's current price. View analysts' price targets for Opiant Pharmaceuticals.

Media coverage about OPNT stock has been trending very negative on Wednesday, InfoTrie reports. The research firm ranks the sentiment of media coverage by reviewing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Opiant Pharmaceuticals earned a news impact score of -3.3 on InfoTrie's scale. They also gave media coverage about the technology company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the company's share price in the near term. View the latest news aboutOpiant Pharmaceuticals.

Opiant Pharmaceuticals saw a decrease in short interest in March. As of March 13th, there was short interest totaling 4,800 shares, a decrease of 30.4% from the February 27th total of 6,900 shares. Based on an average daily volume of 27,500 shares, the days-to-cover ratio is currently 0.2 days. Approximately 0.1% of the shares of the company are sold short. View Opiant Pharmaceuticals' Current Options Chain.

Some companies that are related to Opiant Pharmaceuticals include Jaguar Mining (JAGGF), Fission Uranium (FCUUF), Mountain Province Diamonds (MPVDF), Rubicon Minerals (RBYCF), Atlatsa Resources (ATLRF), Santa Fe Gold (SFEG), Amerigo Resources (ARREF), Pacific Booker Minerals (PBMLF), Wealth Minerals (WMLLF), Quantum Materials (QTMM), Silver Bull Resources (SVBL), Bullfrog Gold (BFGC), US Gold (USAU), Dakota Territory Resource (DTRC) and Quaterra Resources (QTRRF).

Based on aggregate information from My MarketBeat watchlists, some companies that other Opiant Pharmaceuticals investors own include AcelRx Pharmaceuticals (ACRX), Cara Therapeutics (CARA), Vodafone Group (VOD), Synchrony Financial (SYF), Cyberark Software (CYBR), AT&T (T), Vodafone Group (VOD), Corbus Pharmaceuticals (CRBP), Cronos Group (CRON) and Agenus (AGEN).

Opiant Pharmaceuticals trades on the NASDAQ under the ticker symbol "OPNT."

Shares of OPNT can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of OPNT stock can currently be purchased for approximately $9.70.

Opiant Pharmaceuticals has a market capitalization of $41.13 million and generates $40.52 million in revenue each year. The technology company earns $11.59 million in net income (profit) each year or $0.20 on an earnings per share basis. Opiant Pharmaceuticals employs 16 workers across the globe. View additional information about Opiant Pharmaceuticals.

The official website for Opiant Pharmaceuticals is http://www.opiant.com/.

Opiant Pharmaceuticals' mailing address is 233 WILSHIRE BLVD. SUITE 280, SANTA MONICA CA, 90401. The technology company can be reached via phone at 310-598-5410 or via email at [email protected]